Diagnostic Performance of 
      <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from
      the CONDOR Phase III, Multicenter Study

Morris, Michael J.; Rowe, Steven P.; Gorin, Michael A.; Saperstein, Lawrence; Pouliot, Frédéric; Josephson, David A.; Wong, Jeffrey Y.C.; Pantel, Austin R; Cho, Steve Y.; Gage, Kenneth L; Piert, Morand; Iagaru, Andrei; Pollard, Janet H.; Wong, Vivien; Jensen, Jessica K; Lin, Tess E; Stambler, Nancy; Carroll, Peter R.; Siegel, Barry A.

doi:10.1158/1078-0432.CCR-20-4573

Record: found
Abstract: not found
Article: not found

Diagnostic Performance of ¹⁸F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

Author(s): Michael J. Morris , Steven P. Rowe , Michael A. Gorin , Lawrence Saperstein , Frédéric Pouliot , David Josephson , Jeffrey Y.C. Wong , Austin R. Pantel , Steve Y. Cho , Kenneth L. Gage , Morand Piert , Andrei Iagaru , Janet H. Pollard , Vivien Wong , Jessica Jensen , Tess Lin , Nancy Stambler , Peter R. Carroll , Barry A. Siegel

Publication date (Electronic): February 23 2021

Journal: Clinical Cancer Research

Publisher: American Association for Cancer Research (AACR)

Read this article at

ScienceOpenPublisher PMC

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d1713363e319">Current FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule prostate-specific membrane antigen-targeted PET radiotracer. CONDOR was a prospective study designed to determine the performance of 18F-DCFPyL-PET/CT in patients with BCR and uninformative standard imaging. </p>